Trial Profile
A pilot, double-blind crossover trial of the glucocorticoid antagonist mifepristone (RU-486) in the treatment of depression in patients with Parkinson's disease.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Jun 2016
Price :
$35
*
At a glance
- Drugs Mifepristone (Primary)
- Indications Depression
- Focus Therapeutic Use
- 31 Aug 2011 New trial record